Baidu
map

J Ethnopharmacol:胃复春通过miR-26a-5p介导的失稳和MAPK信号通路的失活靶向KPNA2抑制胃癌细胞

2024-07-14 紫菀款冬 MedSci原创 发表于威斯康星

探讨胃复春(WFC)是否具有抑制胃癌细胞恶性的作用,并探讨其分子基础及相关的分子和细胞特征。

背景:胃癌(GC)是癌症相关死亡的主要原因,是全球医疗保健的一大挑战。尽管已经采取了预防胃癌的治疗策略,但未满足的临床需求仍然是胃癌患者持续存在的问题。

胃复春(WFC)是一种常用的治疗萎缩性胃炎和肠化生的中药,由红参、香茶菜、枳壳组成,具有健脾益气、活血解毒的功效。WFC可以通过调节与炎症、过度自身免疫、细胞应激和致病性再生相关的失调信号通路,以及通过抑制幽门螺杆菌(Hp)影响基因表达模式和重新平衡高度多样化的胃微生物生态系统来改善患者预后。迄今为止,其对胃癌(GC)的抗肿瘤作用及其作用机制尚不清楚。

研究目的:探讨WFC是否具有抑制胃癌细胞恶性的作用,并探讨其分子基础及相关的分子和细胞特征。

方法:用WFC处理胃癌细胞系和正常胃上皮细胞。采用CCK8法、caspase-3活性法、粘附法、microRNA数据库分析、转染法、RT-PCR法、Western Blotting法(检测cleaved caspase-3、cleaved PARP,、β-integrin、KPNA2、E-Cadherin、N-Cadherin、ERK1/2、p38、JNK、和GAPDH)、信号通路分析、体内GC模型(利用幽门螺杆菌和MNU作为C57BL/6小鼠胃癌的诱导剂)等方法探讨WFC作用于胃癌细胞的特征变化及分子机制。

结果:数据表明,WFC抑制胃癌的恶性细胞表型,这种抑制作用是通过下调致癌基因KPNA2的表达来介导的。此外,WFC通过miR-26a-5p介导的基因沉默和丝裂原活化蛋白激酶(MAPK)的失活磷酸化动力学下调KPNA2。动物模型进一步证实了WFC对胃癌细胞行为的抑制作用。

结论:WFC可能通过降低KPNA2水平对胃癌细胞的恶性有抑制作用。此外,WFC诱导的miR-26a-5p拯救和MAPK通路失活导致KPNA2表达下调。因此,该研究结果表明WFC是对抗GC的潜在治疗选择。

 

原始出处:

Ma L, Hu X, Zhang W, Qi D, Chen L, Yin M. Weifuchun suppresses the malignancy of gastric cancer cells by targeting KPNA2 through miR-26a-5p-mediated destabilization and the deactivation of the MAPK signaling pathway. J Ethnopharmacol. Published online July 9, 2024. doi:10.1016/j.jep.2024.118538

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2214827, encodeId=2092221482eba, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Jul 14 10:48:20 CST 2024, time=2024-07-14, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2214823, encodeId=7d0d22148231b, content=学习了。好东西。, beContent=null, objectType=article, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c52a105407, createdName=check, createdTime=Sun Jul 14 10:20:56 CST 2024, time=2024-07-14, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2214821, encodeId=e0c42214821d9, content=<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a> <a href='/topic/show?id=675611660168' target=_blank style='color:#2F92EE;'>#MAPK信号#</a> <a href='/topic/show?id=20cc11660269' target=_blank style='color:#2F92EE;'>#胃复春#</a> <a href='/topic/show?id=f88711660328' target=_blank style='color:#2F92EE;'>#KPNA2#</a> <a href='/topic/show?id=6eb8116604d9' target=_blank style='color:#2F92EE;'>#miR-26a-5p#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=116603, encryptionId=f88711660328, topicName=KPNA2), TopicDto(id=116601, encryptionId=675611660168, topicName=MAPK信号), TopicDto(id=116604, encryptionId=6eb8116604d9, topicName=miR-26a-5p), TopicDto(id=116602, encryptionId=20cc11660269, topicName=胃复春), TopicDto(id=83220, encryptionId=f9e2832202f, topicName=胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cade5395722, createdName=梅斯管理员, createdTime=Sun Jul 14 09:17:05 CST 2024, time=2024-07-14, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2214846, encodeId=ad612214846b3, content=签到学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Sun Jul 14 14:17:10 CST 2024, time=2024-07-14, status=1, ipAttribution=贵州省)]
    2024-07-14 1209e435m98(暂无昵称) 来自浙江省

    学习了,谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2214827, encodeId=2092221482eba, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Jul 14 10:48:20 CST 2024, time=2024-07-14, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2214823, encodeId=7d0d22148231b, content=学习了。好东西。, beContent=null, objectType=article, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c52a105407, createdName=check, createdTime=Sun Jul 14 10:20:56 CST 2024, time=2024-07-14, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2214821, encodeId=e0c42214821d9, content=<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a> <a href='/topic/show?id=675611660168' target=_blank style='color:#2F92EE;'>#MAPK信号#</a> <a href='/topic/show?id=20cc11660269' target=_blank style='color:#2F92EE;'>#胃复春#</a> <a href='/topic/show?id=f88711660328' target=_blank style='color:#2F92EE;'>#KPNA2#</a> <a href='/topic/show?id=6eb8116604d9' target=_blank style='color:#2F92EE;'>#miR-26a-5p#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=116603, encryptionId=f88711660328, topicName=KPNA2), TopicDto(id=116601, encryptionId=675611660168, topicName=MAPK信号), TopicDto(id=116604, encryptionId=6eb8116604d9, topicName=miR-26a-5p), TopicDto(id=116602, encryptionId=20cc11660269, topicName=胃复春), TopicDto(id=83220, encryptionId=f9e2832202f, topicName=胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cade5395722, createdName=梅斯管理员, createdTime=Sun Jul 14 09:17:05 CST 2024, time=2024-07-14, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2214846, encodeId=ad612214846b3, content=签到学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Sun Jul 14 14:17:10 CST 2024, time=2024-07-14, status=1, ipAttribution=贵州省)]
    2024-07-14 check 来自河南省

    学习了。好东西。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2214827, encodeId=2092221482eba, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Jul 14 10:48:20 CST 2024, time=2024-07-14, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2214823, encodeId=7d0d22148231b, content=学习了。好东西。, beContent=null, objectType=article, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c52a105407, createdName=check, createdTime=Sun Jul 14 10:20:56 CST 2024, time=2024-07-14, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2214821, encodeId=e0c42214821d9, content=<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a> <a href='/topic/show?id=675611660168' target=_blank style='color:#2F92EE;'>#MAPK信号#</a> <a href='/topic/show?id=20cc11660269' target=_blank style='color:#2F92EE;'>#胃复春#</a> <a href='/topic/show?id=f88711660328' target=_blank style='color:#2F92EE;'>#KPNA2#</a> <a href='/topic/show?id=6eb8116604d9' target=_blank style='color:#2F92EE;'>#miR-26a-5p#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=116603, encryptionId=f88711660328, topicName=KPNA2), TopicDto(id=116601, encryptionId=675611660168, topicName=MAPK信号), TopicDto(id=116604, encryptionId=6eb8116604d9, topicName=miR-26a-5p), TopicDto(id=116602, encryptionId=20cc11660269, topicName=胃复春), TopicDto(id=83220, encryptionId=f9e2832202f, topicName=胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cade5395722, createdName=梅斯管理员, createdTime=Sun Jul 14 09:17:05 CST 2024, time=2024-07-14, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2214846, encodeId=ad612214846b3, content=签到学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Sun Jul 14 14:17:10 CST 2024, time=2024-07-14, status=1, ipAttribution=贵州省)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2214827, encodeId=2092221482eba, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Jul 14 10:48:20 CST 2024, time=2024-07-14, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2214823, encodeId=7d0d22148231b, content=学习了。好东西。, beContent=null, objectType=article, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c52a105407, createdName=check, createdTime=Sun Jul 14 10:20:56 CST 2024, time=2024-07-14, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2214821, encodeId=e0c42214821d9, content=<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a> <a href='/topic/show?id=675611660168' target=_blank style='color:#2F92EE;'>#MAPK信号#</a> <a href='/topic/show?id=20cc11660269' target=_blank style='color:#2F92EE;'>#胃复春#</a> <a href='/topic/show?id=f88711660328' target=_blank style='color:#2F92EE;'>#KPNA2#</a> <a href='/topic/show?id=6eb8116604d9' target=_blank style='color:#2F92EE;'>#miR-26a-5p#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=116603, encryptionId=f88711660328, topicName=KPNA2), TopicDto(id=116601, encryptionId=675611660168, topicName=MAPK信号), TopicDto(id=116604, encryptionId=6eb8116604d9, topicName=miR-26a-5p), TopicDto(id=116602, encryptionId=20cc11660269, topicName=胃复春), TopicDto(id=83220, encryptionId=f9e2832202f, topicName=胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cade5395722, createdName=梅斯管理员, createdTime=Sun Jul 14 09:17:05 CST 2024, time=2024-07-14, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2214846, encodeId=ad612214846b3, content=签到学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Sun Jul 14 14:17:10 CST 2024, time=2024-07-14, status=1, ipAttribution=贵州省)]
    2024-07-14 屋顶瞄爱赏月 来自贵州省

    签到学习

    0

相关资讯

Nat Med:徐瑞华教授团队发现呋喹替尼对晚期胃癌二线治疗效果显著(FRUTIGA研究)

尽管近年来抗HER2治疗、免疫治疗和Claudin18.2治疗等新兴药物相继推动了晚期胃癌线治疗的进步,但二线治疗的发展相对缓慢,临床选择依然有限,临床需求亟待满足。呋喹替尼是我国原研的一种高选择性、

无进展生存期翻倍!中肿徐瑞华团队:这种策略改善胃癌多个临床结局

研究旨在评估呋喹替尼+紫杉醇与安慰剂+紫杉醇作为晚期胃/胃食管交界处腺癌患者二线治疗的疗效和安全性。

邓婷教授:2024年ASCO胃癌围手术期免疫治疗进展

邓教授系统地阐述了胃癌围手术期治疗的免疫、化疗及多维度研究,尤其是免疫治疗在这一领域的应用与进展,为与会者提供了新的学术视角和临床指导。

骆卉妍教授:2024ASCO胃癌靶向研究新进展

本文将详细梳理各项研究的关键发现,为读者呈现胃癌治疗领域的最新动态。

邓婷教授:2024年ASCO胃癌围手术期化疗新策略及生物标志物探索

在本次大会的首场专题——胃癌ASCO速递中,天津医科大学肿瘤医院的邓婷教授为我们深入探讨了化疗及多维度研究在胃癌治疗中的应用,进一步丰富了我们对胃癌治疗策略的认识。

BMJ:徐瑞华教授团队发现替雷利珠单抗联合化疗能显著延长晚期胃癌患者的总生存期(RATIONALE-305研究)

晚期胃癌的主要治疗手段是全身系统性治疗,包括化疗、靶向治疗等,然而,传统的化疗药物在晚期胃癌中的疗效已到瓶颈期,晚期胃癌患者的中位生存期在1年左右,难以满足患者的治疗需求。近年来,以PD-1抗体为代表

根除幽门螺杆菌,远离胃癌!北肿李文庆团队:高遗传风险人群患癌风险降低55%!

根除幽门螺杆菌或可消除胃癌高遗传风险带来的影响,在现有一级预防措施的基础上,针对不同遗传风险调整个体干预和预防策略,更有利于预防胃癌的发生。

孔大陆教授组稿|杨艳鹏:肿瘤相关成纤维细胞在胃癌化疗耐药中的作用

本期「专家组稿」由天津医科大学肿瘤医院孔大陆教授担任执行主编,他将与杨艳鹏医生在第五期内容中分享肿瘤相关成纤维细胞在胃癌化疗耐药中的作用,为医者和患者提供更多参考。

【论著】| 贝伐珠单抗辅助PD-1抑制剂治疗胃癌对血清miR-20a-5p和miR-515-3p的影响研究

本研究旨在探究贝伐珠单抗辅助PD-1抑制剂治疗胃癌对血清miR-20a-5p和miR-515-3p的影响。

Baidu
map
Baidu
map
Baidu
map